Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens

BACKGROUND Recent studies suggest that insulinoma‐associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer cytopathology 2018-04, Vol.126 (4), p.243-252
Hauptverfasser: Doxtader, Erika E., Mukhopadhyay, Sanjay
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 252
container_issue 4
container_start_page 243
container_title Cancer cytopathology
container_volume 126
creator Doxtader, Erika E.
Mukhopadhyay, Sanjay
description BACKGROUND Recent studies suggest that insulinoma‐associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with paired surgical pathology specimens, and to compare its sensitivity and specificity with those of synaptophysin (SYN), chromogranin (CHR), and CD56 for neuroendocrine lung tumors. METHODS Seventy‐four primary lung neoplasms diagnosed on cytology were stained with INSM1, SYN, CHR, and CD56: 41 small cell lung carcinomas (SCLCs), 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma and 1 poorly differentiated non–small cell lung carcinoma, not otherwise specified. In 20 cases, a paired surgical pathology specimen was also stained with INSM1. RESULTS INSM1 was positive in 48 of 52 primary lung neuroendocrine neoplasms (92%), including 38 of 41 SCLCs (93%), the only LCNEC (100%), and 9 of 10 carcinoid tumors (90%), and it was negative in all 22 non‐neuroendocrine primary lung tumors. For SCLC, the sensitivity of INSM1 (93%) was lower than the sensitivity of CD56 (100%), equal to the sensitivity of SYN (93%), and higher than the sensitivity of CHR (35%). For carcinoid tumors, the sensitivity of INSM1 (90%) was lower than the sensitivity of all other markers (100% each). The specificity of INSM1 for neuroendocrine neoplasms as a group was 100%. INSM1 staining was concordant with surgical pathology specimens in all 20 paired cases. CONCLUSIONS INSM1 can be used in cytopathology cell blocks, and it is sensitive and highly specific for neuroendocrine lung tumors. INSM1 staining in cytology cell blocks correlates well with surgical pathology specimens. Cancer Cytopathol 2018;126:243‐52. © 2018 American Cancer Society. Insulinoma‐associated protein 1, a nuclear marker of neuroendocrine neoplasms, can be reliably used in Cellient cell blocks from lung tumors, and it combines high sensitivity (slightly less than the sensitivity of CD56) with high specificity (similar to the specificity of chromogranin). Insulinoma‐associated protein 1 staining in cytology cell block samples correlates well with corresponding surgical pathology specimens.
doi_str_mv 10.1002/cncy.21972
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1990492963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1990492963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4592-14cf2102195ccac645f33b44e8fcf910eddd3a382254494bbc048407ed37f33e3</originalsourceid><addsrcrecordid>eNp9kc1KHTEUx0Op1I920weQgBsRruZrPrIsF7WC6EbBrkJu5oxEZ5LbnBll6KaP0Gf0SRo76sJFVzmE3_lxzvkT8pWzQ86YOHLBTYeC60p8IFtcS7UoS1l_fKvFzSbZRrxjjNeV4J_IptCyZFzzLfLrLODY-RB7-_T7j0WMztsBGrpOcQAfKKceqaUIAf3gH4Da0FBcg_Otd7S36R4SjS0NMKYIoYku-QC0G8Nt_ovrzmKPNIvcNMQu3k5zc599n8lGazuELy_vDrk-Ob5afl-cX56eLb-dL5wqtFhw5VrBWV6wcM66UhWtlCuloG5dqzmDpmmklbUQhVJarVaOqVqxChpZZRLkDtmfvXmnnyPgYHqPDrrO5gFHNFxrprTQpczo3jv0Lo4p5OmMYEIVUlSiytTBTLkUERO0Zp18PsVkODPPkZjnSMy_SDK8-6IcVz00b-hrBhngM_DoO5j-ozLLi-WPWfoXWuiZLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2024532727</pqid></control><display><type>article</type><title>Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Doxtader, Erika E. ; Mukhopadhyay, Sanjay</creator><creatorcontrib>Doxtader, Erika E. ; Mukhopadhyay, Sanjay</creatorcontrib><description>BACKGROUND Recent studies suggest that insulinoma‐associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with paired surgical pathology specimens, and to compare its sensitivity and specificity with those of synaptophysin (SYN), chromogranin (CHR), and CD56 for neuroendocrine lung tumors. METHODS Seventy‐four primary lung neoplasms diagnosed on cytology were stained with INSM1, SYN, CHR, and CD56: 41 small cell lung carcinomas (SCLCs), 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma and 1 poorly differentiated non–small cell lung carcinoma, not otherwise specified. In 20 cases, a paired surgical pathology specimen was also stained with INSM1. RESULTS INSM1 was positive in 48 of 52 primary lung neuroendocrine neoplasms (92%), including 38 of 41 SCLCs (93%), the only LCNEC (100%), and 9 of 10 carcinoid tumors (90%), and it was negative in all 22 non‐neuroendocrine primary lung tumors. For SCLC, the sensitivity of INSM1 (93%) was lower than the sensitivity of CD56 (100%), equal to the sensitivity of SYN (93%), and higher than the sensitivity of CHR (35%). For carcinoid tumors, the sensitivity of INSM1 (90%) was lower than the sensitivity of all other markers (100% each). The specificity of INSM1 for neuroendocrine neoplasms as a group was 100%. INSM1 staining was concordant with surgical pathology specimens in all 20 paired cases. CONCLUSIONS INSM1 can be used in cytopathology cell blocks, and it is sensitive and highly specific for neuroendocrine lung tumors. INSM1 staining in cytology cell blocks correlates well with surgical pathology specimens. Cancer Cytopathol 2018;126:243‐52. © 2018 American Cancer Society. Insulinoma‐associated protein 1, a nuclear marker of neuroendocrine neoplasms, can be reliably used in Cellient cell blocks from lung tumors, and it combines high sensitivity (slightly less than the sensitivity of CD56) with high specificity (similar to the specificity of chromogranin). Insulinoma‐associated protein 1 staining in cytology cell block samples correlates well with corresponding surgical pathology specimens.</description><identifier>ISSN: 1934-662X</identifier><identifier>EISSN: 1934-6638</identifier><identifier>DOI: 10.1002/cncy.21972</identifier><identifier>PMID: 29360191</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Cellular biology ; cytopathology ; insulinoma‐associated protein 1 (INSM1) ; lung ; Lung cancer ; neuroendocrine ; Neuroendocrine tumors ; Pathology ; small cell carcinoma ; Squamous cell carcinoma ; Tumors</subject><ispartof>Cancer cytopathology, 2018-04, Vol.126 (4), p.243-252</ispartof><rights>2018 American Cancer Society</rights><rights>2018 American Cancer Society.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4592-14cf2102195ccac645f33b44e8fcf910eddd3a382254494bbc048407ed37f33e3</citedby><cites>FETCH-LOGICAL-c4592-14cf2102195ccac645f33b44e8fcf910eddd3a382254494bbc048407ed37f33e3</cites><orcidid>0000-0002-6425-6537</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncy.21972$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncy.21972$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29360191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doxtader, Erika E.</creatorcontrib><creatorcontrib>Mukhopadhyay, Sanjay</creatorcontrib><title>Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens</title><title>Cancer cytopathology</title><addtitle>Cancer Cytopathol</addtitle><description>BACKGROUND Recent studies suggest that insulinoma‐associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with paired surgical pathology specimens, and to compare its sensitivity and specificity with those of synaptophysin (SYN), chromogranin (CHR), and CD56 for neuroendocrine lung tumors. METHODS Seventy‐four primary lung neoplasms diagnosed on cytology were stained with INSM1, SYN, CHR, and CD56: 41 small cell lung carcinomas (SCLCs), 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma and 1 poorly differentiated non–small cell lung carcinoma, not otherwise specified. In 20 cases, a paired surgical pathology specimen was also stained with INSM1. RESULTS INSM1 was positive in 48 of 52 primary lung neuroendocrine neoplasms (92%), including 38 of 41 SCLCs (93%), the only LCNEC (100%), and 9 of 10 carcinoid tumors (90%), and it was negative in all 22 non‐neuroendocrine primary lung tumors. For SCLC, the sensitivity of INSM1 (93%) was lower than the sensitivity of CD56 (100%), equal to the sensitivity of SYN (93%), and higher than the sensitivity of CHR (35%). For carcinoid tumors, the sensitivity of INSM1 (90%) was lower than the sensitivity of all other markers (100% each). The specificity of INSM1 for neuroendocrine neoplasms as a group was 100%. INSM1 staining was concordant with surgical pathology specimens in all 20 paired cases. CONCLUSIONS INSM1 can be used in cytopathology cell blocks, and it is sensitive and highly specific for neuroendocrine lung tumors. INSM1 staining in cytology cell blocks correlates well with surgical pathology specimens. Cancer Cytopathol 2018;126:243‐52. © 2018 American Cancer Society. Insulinoma‐associated protein 1, a nuclear marker of neuroendocrine neoplasms, can be reliably used in Cellient cell blocks from lung tumors, and it combines high sensitivity (slightly less than the sensitivity of CD56) with high specificity (similar to the specificity of chromogranin). Insulinoma‐associated protein 1 staining in cytology cell block samples correlates well with corresponding surgical pathology specimens.</description><subject>Cellular biology</subject><subject>cytopathology</subject><subject>insulinoma‐associated protein 1 (INSM1)</subject><subject>lung</subject><subject>Lung cancer</subject><subject>neuroendocrine</subject><subject>Neuroendocrine tumors</subject><subject>Pathology</subject><subject>small cell carcinoma</subject><subject>Squamous cell carcinoma</subject><subject>Tumors</subject><issn>1934-662X</issn><issn>1934-6638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1KHTEUx0Op1I920weQgBsRruZrPrIsF7WC6EbBrkJu5oxEZ5LbnBll6KaP0Gf0SRo76sJFVzmE3_lxzvkT8pWzQ86YOHLBTYeC60p8IFtcS7UoS1l_fKvFzSbZRrxjjNeV4J_IptCyZFzzLfLrLODY-RB7-_T7j0WMztsBGrpOcQAfKKceqaUIAf3gH4Da0FBcg_Otd7S36R4SjS0NMKYIoYku-QC0G8Nt_ovrzmKPNIvcNMQu3k5zc599n8lGazuELy_vDrk-Ob5afl-cX56eLb-dL5wqtFhw5VrBWV6wcM66UhWtlCuloG5dqzmDpmmklbUQhVJarVaOqVqxChpZZRLkDtmfvXmnnyPgYHqPDrrO5gFHNFxrprTQpczo3jv0Lo4p5OmMYEIVUlSiytTBTLkUERO0Zp18PsVkODPPkZjnSMy_SDK8-6IcVz00b-hrBhngM_DoO5j-ozLLi-WPWfoXWuiZLQ</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Doxtader, Erika E.</creator><creator>Mukhopadhyay, Sanjay</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6425-6537</orcidid></search><sort><creationdate>201804</creationdate><title>Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens</title><author>Doxtader, Erika E. ; Mukhopadhyay, Sanjay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4592-14cf2102195ccac645f33b44e8fcf910eddd3a382254494bbc048407ed37f33e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cellular biology</topic><topic>cytopathology</topic><topic>insulinoma‐associated protein 1 (INSM1)</topic><topic>lung</topic><topic>Lung cancer</topic><topic>neuroendocrine</topic><topic>Neuroendocrine tumors</topic><topic>Pathology</topic><topic>small cell carcinoma</topic><topic>Squamous cell carcinoma</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Doxtader, Erika E.</creatorcontrib><creatorcontrib>Mukhopadhyay, Sanjay</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer cytopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doxtader, Erika E.</au><au>Mukhopadhyay, Sanjay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens</atitle><jtitle>Cancer cytopathology</jtitle><addtitle>Cancer Cytopathol</addtitle><date>2018-04</date><risdate>2018</risdate><volume>126</volume><issue>4</issue><spage>243</spage><epage>252</epage><pages>243-252</pages><issn>1934-662X</issn><eissn>1934-6638</eissn><abstract>BACKGROUND Recent studies suggest that insulinoma‐associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with paired surgical pathology specimens, and to compare its sensitivity and specificity with those of synaptophysin (SYN), chromogranin (CHR), and CD56 for neuroendocrine lung tumors. METHODS Seventy‐four primary lung neoplasms diagnosed on cytology were stained with INSM1, SYN, CHR, and CD56: 41 small cell lung carcinomas (SCLCs), 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma and 1 poorly differentiated non–small cell lung carcinoma, not otherwise specified. In 20 cases, a paired surgical pathology specimen was also stained with INSM1. RESULTS INSM1 was positive in 48 of 52 primary lung neuroendocrine neoplasms (92%), including 38 of 41 SCLCs (93%), the only LCNEC (100%), and 9 of 10 carcinoid tumors (90%), and it was negative in all 22 non‐neuroendocrine primary lung tumors. For SCLC, the sensitivity of INSM1 (93%) was lower than the sensitivity of CD56 (100%), equal to the sensitivity of SYN (93%), and higher than the sensitivity of CHR (35%). For carcinoid tumors, the sensitivity of INSM1 (90%) was lower than the sensitivity of all other markers (100% each). The specificity of INSM1 for neuroendocrine neoplasms as a group was 100%. INSM1 staining was concordant with surgical pathology specimens in all 20 paired cases. CONCLUSIONS INSM1 can be used in cytopathology cell blocks, and it is sensitive and highly specific for neuroendocrine lung tumors. INSM1 staining in cytology cell blocks correlates well with surgical pathology specimens. Cancer Cytopathol 2018;126:243‐52. © 2018 American Cancer Society. Insulinoma‐associated protein 1, a nuclear marker of neuroendocrine neoplasms, can be reliably used in Cellient cell blocks from lung tumors, and it combines high sensitivity (slightly less than the sensitivity of CD56) with high specificity (similar to the specificity of chromogranin). Insulinoma‐associated protein 1 staining in cytology cell block samples correlates well with corresponding surgical pathology specimens.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29360191</pmid><doi>10.1002/cncy.21972</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6425-6537</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1934-662X
ispartof Cancer cytopathology, 2018-04, Vol.126 (4), p.243-252
issn 1934-662X
1934-6638
language eng
recordid cdi_proquest_miscellaneous_1990492963
source Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals
subjects Cellular biology
cytopathology
insulinoma‐associated protein 1 (INSM1)
lung
Lung cancer
neuroendocrine
Neuroendocrine tumors
Pathology
small cell carcinoma
Squamous cell carcinoma
Tumors
title Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A19%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulinoma%E2%80%90associated%20protein%201%20is%20a%20sensitive%20and%20specific%20marker%20of%20neuroendocrine%20lung%20neoplasms%20in%20cytology%20specimens&rft.jtitle=Cancer%20cytopathology&rft.au=Doxtader,%20Erika%20E.&rft.date=2018-04&rft.volume=126&rft.issue=4&rft.spage=243&rft.epage=252&rft.pages=243-252&rft.issn=1934-662X&rft.eissn=1934-6638&rft_id=info:doi/10.1002/cncy.21972&rft_dat=%3Cproquest_cross%3E1990492963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2024532727&rft_id=info:pmid/29360191&rfr_iscdi=true